Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that […]